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Cathelicidins are a family of peptides thought to pro-
vide an innate defensive barrier against a variety of
potential microbial pathogens. The human and
mouse cathelicidins (LL-37 and CRAMP, respect-
ively) are expressed at select epithelial interfaces
where they have been proposed to kill a number of
gram-negative and gram-positive bacteria. To deter-
mine if these peptides play a part in the protection
of skin against wound infections, the anti-microbial
activity of LL-37 and CRAMP was determined
against the common wound pathogen group A
Streptococcus, and their expression was examined after
cutaneous injury. We observed a large increase in the
expression of cathelicidins in human and murine skin
after sterile incision, or in mouse following infection
by group A Streptococcus. The appearance of cathelici-
dins in skin was due to both synthesis within epider-
mal keratinocytes and deposition from granulocyctes
that migrate to the site of injury. Synthesis and
deposition in the wound was accompanied by pro-
cessing from the inactive prostorage form to the
mature C-terminal peptide. Analysis of anti-micro-
bial activity of this C-terminal peptide against group
A Streptococcus revealed that both LL-37 and CRAMP
potently inhibited bacterial growth. Action against
group A Streptococcus occurred in conditions that typ-
ically abolish the activity of anti-microbial peptides
against other organisms. Thus, cathelicidins are well
suited to provide defense against infections due to
group A Streptococcus, and represent an important
element of cutaneous innate immunity. Key words:
bacteria/infection/keratinocytes/skin/wound healing. J Invest
Dermatol 117:91±97, 2001
T
he term ``anti-microbial peptide'' has been used to
describe a large number of small proteins that can kill
or inhibit the growth of a wide variety of microbes.
Plants, insects, and animals have evolved to produce a
great variety of such peptides that are thought to be
protective against pathogenic microorganisms (Boman, 1998; Ganz
and Lehrer, 1999). More recently, the principles of anti-microbial
peptide defense observed in other species have been applied to
understanding human resistance to disease. The diversity of anti-
microbial peptides, however, many exhibiting alternative biologic
functions or acting synergistically, has made the relative contribu-
tion of individual peptides to host defense dif®cult to determine.
Known mammalian anti-microbial peptides belong to four main
groups: a-defensins, b-defensins, q-defensins, and cathelicidins.
Depending on the species, most of these peptides are found in
leukocyte granules and at a variety of epithelia. Anti-microbial
peptides are generally the product of post-translational processing
from an immature preproprotein to an active mature peptide.
Cathelicidins are the most structurally diverse anti-microbial gene
family in this mature C-terminal domain (Zanetti et al, 1995), with
mature products that include peptides rich in proline and arginine
(i.e., PR-39), those that form disul®de bonds and b-sheet structures
similar to defensins (i.e., protegrins), and a-helical peptides (i.e.,
LL-37). Unlike defensins, LL-37 is the only member of the
cathelicidin gene family found in humans (Gudmundsson et al,
1996), and closely resembles CRAMP, the sole member of this
gene family in mice (Gallo et al, 1997).
Anti-microbial peptides have been proposed to provide innate
immune defense at the epithelial interface with the external
environment. Consistent with this function, expression of b-
defensins and cathelicidins occurs in cells directly exposed to
microbial pathogens (Goldman et al, 1997; Stolzenberg et al, 1997;
Bals et al, 1998). For example, mucosal epithelia of the airways
express both b-defensins and cathelicidins, thus presenting a
theoretical inhibitory environment for microbial growth.
Cathelicidins and b-defensins each inhibit the growth in vitro of
several different bacterial species that are potential respiratory
pathogens. This anti-microbial activity, however, is highly sensitive
in some cases to the culture conditions and easily inactivated by
alterations in the ionic strength or the addition of other molecules
present at the mucosal interface (Goldman et al, 1997; Bals et al,
1998; Johansson et al, 1998). Inactivation of anti-microbial peptides
by high ionic strength environments has been proposed as a possible
contributor to the pathogenesis of pulmonary infections in cystic
®brosis patients (Goldman et al, 1997); however, the sensitivity of
anti-microbial peptides to inactivation casts some doubt on their
ef®cacy as a primary defense system.
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The function of cathelicidins in human skin is incompletely
understood. Human epidermis does not synthesize signi®cant
amounts of anti-microbial peptides in a constitutive manner despite
the high degree of potential microbial exposure. Production of b-
defensins and cathelicidins has been seen in diseased skin (Frohm et
al, 1997; Harder et al, 1997), but a relationship between expression
and disease pathogenesis has not been established. Furthermore,
many potential skin pathogens have not been studied for their
susceptibility to anti-microbial peptides. In this study we investi-
gated whether injury can initiate cathelicidin expression in the skin.
We showed that after injury human and mouse skin rapidly
increases expression of cathelicidins in the epidermis and within the
wound itself. Analysis of the biologic activity of cathelicidin against
the important human skin pathogen group A Streptococcus (GAS)
demonstrated that cathelicidins are highly active against this
organism. Unlike other potential pathogenic targets for anti-
microbial peptides, the ability of cathelicidins to inhibit GAS
growth is stable under a wide range of relevant environmental
conditions. These observations suggest cathelicidins can play an
important part in innate immune defense of wound repair.
MATERIALS AND METHODS
Antibody production and western blot For antibody production a
synthetic 16 amino acid CRAMP peptide fragment (GQKIKN-
FIQKLVPQPE-OH) corresponding to amino acids 18±33 of the mature
CRAMP protein was bound to Keyhole Limpet Hemocyanin and
injected subcutaneously in rabbits (QCB, Hopkinton, MA). Rabbits
were boosted four times with this peptide and bled 10 d after boosts.
Anti-sera were checked by enzyme-linked immunosorbent assay and
speci®c anti-CRAMP antibody puri®ed via af®nity chromatography over
a sepharose column conjugated with CRAMP peptide fragment used as
immunogen. To demonstrate speci®city, af®nity puri®ed antibody was
used to detect the 16 amino acid peptide fragment, or native CRAMP
from murine bone marrow extracts. Bone marrow samples were boiled
in sodium dodecyl sulfate (SDS) loading buffer containing 10% 2-
mercaptoethanol for 5 min prior to electrophoresis. Proteins were
separated via a 3.5±20% gradient SDS/polyacrylamide gel electrophoresis,
then transferred on to a nitrocellulose membrane (MSI, Westborough,
MA) or silver stained (Bio-Rad, Hercules, CA) for total protein. Rabbit
antibodies were detected using a goat anti-rabbit IgG conjugated with
horseradish peroxidase (Dako A/S, Carpinteria, CA) and developed using
chemiluminescence [(1 min incubation in 0.1 M Tris pH 8.5, 0.01%
H2O2, 1.25 mM 3-aminophthalhydrazine (Fluka, Buchs, Switzerland),
0.25 mM coumaric acid (Sigma, St Louis, MO)]. Anti-CRAMP
antibody was speci®c for two bands of »17 and 5 kDa, corresponding to
the predicted sizes of the Pro-CRAMP and mature CRAMP,
respectively (Fig 1, lane B). Similar methods using 4±20% Tris/Glycine
gels (Novex, San Diego, CA) were used for western blots on normal or
wounded skin extracts. Antibody to LL-37 was prepared as previously
described (Gudmundsson et al, 1996).
Bacterial strains GAS strain NZ131 is a M49 serotype skin isolate
from a patient who developed acute poststreptococcal glomerulonephritis
(Simon and Ferretti, 1991). GAS strains 909 (M22), 317/98 (M59), and
1602/99 (M76) were kindly provided by Dr. Bernard Beall from recent
epidemiologic investigations at the Centers for Disease Control in
Atlanta. All GAS isolates possessed M protein gene chromosomal pattern
``E'' and produced the apolipoproteinase opacity factor as is characteristic
for impetigo-causing strains (Bessen and Fischetti, 1990; Bessen et al,
1996). Group B streptococcal strains A909 (serotype Ia), M709 (Ib),
DK23 (II), and K79 (III) were isolated from the blood or spinal ¯uid of
septic neonates (Nizet et al, 1996, 1997). Group C streptococcal isolate
VASD1 was isolated from the blood of an adult patient at the VA
Medical Center, San Diego, CA.
Skin injury models Age- and sex-matched C57BL/6 mice obtained
from Jackson Laboratories (Bar Harbor, ME) were anesthetized by
inhalation of halothane, the hair of the back removed, and 1 cm full
thickness incisions made through the pannicculus carnosis. Mice were
individually housed under aseptic conditions until analysis. For
determination of cathelicidin expression, mice were killed via cervical
dislocation at 6, 12, 24, 72, and 120 h postincision and a 1 cm area
surrounding the wound excised and ®xed in 10% buffered formalin. For
extraction of total proteins used for western blotting of cathelicidins,
crust from 120 h wounds, or unwounded skin, was similarly excised,
pannicculus carnosis removed, tissue weighed, diced, and sonicated for
10 min in a volume of SDS loading buffer (4% SDS, 40% glycerol,
100 mM Tris pH 7.5, 0.05% Bromophenol Blue) proportional to its
mass. In the GAS infection model, paraf®n sections of murine skin were
generously provided by Dr. Joyce C.S. De Azavedo at the University of
Toronto. These hairless, 4 wk old male crl:SKH1(hrhr)Br mice were
injected subcutaneously 24 h prior with 106 colony forming units of
GAS NZ131(M49 serotype) complexed to Cytodex beads as a carrier, or
with Cytodex beads alone (control), as previously described (Betschel et
al, 1998). All procedures were approved by the VA San Diego
Healthcare system subcommittee on animal studies.
Human skin wounds were collected following informed consent by
inducing 0.5 cm full-thickness wounds in the axilla of healthy male
volunteers under aseptic conditions with local anesthesia. At 24, 48, and
120 h after incision, 4 mm punch biopsies were taken from the site of
injury and ®xed in 10% buffered formalin. Apligraft cultured skin
equivalents were generously provided by Dr. Tara Pouyani courtesy of
Organogenisis (Canton, MA) and similarly ®xed for histologic analysis.
Immunohistochemistry Paraf®n-embedded formalin-®xed tissue
sections were re-hydrated in a series of toluene, ethanol, and phosphate-
buffered saline (PBS; 138 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4
7H2O, 1.5 mM KH2PO4, pH 7.3). Endogenous peroxidase activity was
quenched with a 30 min incubation in 0.3% H2O2 in water, and
sections microwaved for 5 min in antigen retrieval solution (0.01 M
citric acid, 0.05 M NaOH pH 6.0). Sections were blocked with 2% goat
serum in PBS then incubated with primary antibody (either 5 mg per ml
rabbit anti LL-37 or 0.8 mg per ml anti CRAMP) in PBS, 0.1% bovine
serum albumin. Sections were washed in PBS and detected with goat
anti-rabbit-horseradish peroxidase (Vectastain ABC Elite Rabbit kit,
Vector Laboratories, Burlingame, CA) and diaminobenzidine substrate
(Sigma) per manufacturers' instructions. In some cases sections were
counterstained with hematoxylin after diaminobenzidine. Speci®city of
the primary antibody reaction was con®rmed in separate experiments by
adsorption of either anti-LL-37 or anti-CRAMP with excess amounts of
the respective synthetic peptide. Speci®city of the secondary antibody
and immunostaining reagents was con®rmed by routine use of rabbit
preimmune sera.
Reverse transcription±polymerase chain reaction (reverse
transcription±PCR) RNA was extracted as previously described
(Chomczynski and Sacchi, 1987) from equal amounts of unwounded
mouse skin, skin 2 or 12 h after a single 1 cm long sterile full-thickness
incision, or from femural bone marrow. cDNA was made from 1 mg of
each RNA with SuperScript II RNase H± Reverse Transcriptase (Gibco
BRL, Rockville, MD). PCR ampli®cation of CRAMP was performed with
oligonucleotides: CRAMP-F1 (GGATGAGAATAAATGAGGCTCTC)
and CRAMP-B2 (TTTAGGAATCCAGAAACAGGC). Ampli®cation
of b-actin was performed with oligonucleotides BACTIN-1 (GGT-
CGTCGACAACGGCTC) and BACTIN-2 (TGCCATGTTCAATG-
GGGTAC). Reactions were run with 2 ml reverse transcription reaction
template and 10 pmol oligos using Platinum PCR SuperMix (Gibco
BRL, MD) in a 50 ml reaction volume. Thermal cycler pro®le: 94°C for
Figure 1. Antibody against CRAMP is speci®c. Lane A: silver-
stained gel from murine bone marrow extract demonstrating multiple
proteins present in extract. Lanes B, C: Western blots using an antibody
against CRAMP described in Materials and Methods. Lane B contains
bone marrow extract and lane C contains a synthetic CRAMP 16 amino
acid fragment used as the immunogen. The antibody speci®cally
recognized native peptides in the marrow extract corresponding to the
predicted size of both the immature and mature cathelicidin peptide.
92 DORSCHNER ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
5 min; 35 cycles of 94°C for 30 s, 60°C for 30 s, 72°C for 1 min; ®nal
extension step of 72°C for 7 min. This protocol was optimized for
maximum visualization of product. Separate ampli®cations were
performed for various cycles (20±35) to con®rm consistency in relative
detection between samples of CRAMP PCR products. Products were
run on a 2.5% NuSieve 3:1 agarose gel (Biowhittaker Molecular
Applications, Walkersville, MD) with Roche DNA molecular weight
marker IX (X174 DNA cleaved with HaeIII) and stained with ethidium
bromide. For con®rmation, the 607 bp PCR product was directly
sequenced and found identical to CRAMP.
Peptide synthesis LL-37 peptide synthesis was performed with an
Applied Biosystems model 430A peptide synthesizer using standard solid-
phase procedures. Starting from t-butoxycarbonyl-Ser(benzyl)-OCH-
phenylacetamidomethyl resin (0.67 mmol per g), t-butoxycarbonyl
amino acid derivatives were used with reactive side chains protected as
follows: serine and threonine, benzyl; lysine, 2-chlorobenzyloxycarbonyl;
glutamate and aspartate, benzyl ester; and arginine, 4-toluenesulfonyl.
Double couplings were performed for arginine, glutamine, and
asparagine residues. The peptides were cleaved from the resins with
liquid hydrogen¯uoride/anisole/methylsul®de (10:1:1, vol/vol/vol) for
60 min at 0°C. The cleavage products were washed with diethylether to
remove scavengers and protecting groups, extracted in 30% acetic acid,
and lyophilized. The peptides were further puri®ed by high-performance
liquid chromatography (Waters, Milford, MA) on a reversed phase Vydac
C18 column (The Separation Group, Hesperia, CA), using a linear
gradient of acetonitrile (15±60% in 40 min) in 0.1% tri¯uoroacetic acid.
The molecular masses were determined with a matrix-assisted laser
desorption/ionization instrument (Lasermat 2000, Finnigan, San Jose,
CA) and were, in all cases, in agreement with the calculated masses.
Puri®cation and N-terminal sequencing of the native mature mouse
cathelicidin CRAMP from granulocytes has shown that this peptide is 33
amino acids with a N-terminus of GLL. Synthetic CRAMP peptide
corresponding to the 33 amino acids: (GLLRKGGEKIGEKLKKIG-
QKIKNFFQKLVPQPE) was synthesized commercially to > 95% purity
as con®rmed by high-performance liquid chromatography and mass
spectrometry (Sigma Genosys, The Woodlands, TX).
Anti-microbial activity assays For assay of anti-microbial activity in
solution, bacteria were grown in sterile tryptic soy broth (Sigma) to early
log phase (OD600 = 0.06). In triplicate, 0.05 ml of bacterial suspension
was added to wells of a 96 well ¯at bottomed tissue culture plate.
Minimal inhibitory concentrations (MIC) of LL-37 or CRAMP were
determined by 2-fold serial dilutions of each peptide. Bacterial growth
was measured by recording the absorbance at 600 nm before and after an
overnight incubation at 37°C. Percent inhibition of bacterial growth, as
compared with controls containing no peptide, was calculated and MIC
values determined based on ability to inhibit 80% or more of bacterial
proliferation. Anti-microbial activity against Escherichia coli was also
assayed in half-strength Mueller-Hinton broth containing Medium E
(16 mM Na+, 30 mM K+, 0.8 mM Mg2+) to compare anti-microbial
activity of synthetic peptides to previously reported values for E. coli
(Bals et al, 1998), and in Luria Broth.
RESULTS
Cathelicidins are induced in the skin following
injury Cathelicidins are expressed in several tissues, including
pulmonary epithelia, gut epithelia, testes, and bone marrow
(Agerberth et al, 1991; Shi et al, 1994; Gallo et al, 1997; Sorensen
et al, 1997; Bals et al, 1998; Wang et al, 1999), but have not been
seen in the epidermis or dermis of normal skin (Frohm et al, 1997).
To determine if cathelicidins are expressed in the skin following
injury and, are therefore, available to provide innate anti-microbial
defense following barrier compromise, sections of murine and
human skin were ®rst evaluated by immunohistochemistry at
various time points after injury with antibodies speci®c to CRAMP
or LL-37. Observation of both mouse and human wounds under
low magni®cation showed abundant and similar patterns of
expression (Fig 2). CRAMP, the sole known murine
cathelicidin, was not detected in normal skin, but rapidly
appeared following injury (Fig 2A, B). Initially, CRAMP was
detected most abundantly in the dermis at the edge of the wound,
and later in the granulation tissue and crust. Expression of CRAMP
in the dermis was mostly located extracellularly with the exception
of staining seen within granulocytes. After re-epithelialization was
complete, CRAMP was no longer detected (data not shown).
Human skin immunostained for the human cathelicidin LL-37
revealed a similar pattern of expression. LL-37 was observed
initially only at the site of injury and later in the granulation tissue
and crust (Fig 2D, E). Speci®city of the antibody staining was
con®rmed on control sections stained with preimmune sera
(Fig 2C, F). These sections showed no staining and were similar
to results obtained previously with these antibodies following
preadsorption with excess LL-37 or CRAMP. Thus, wounding
results in the accumulation of cathelicidin in the skin of humans
and mice.
Under high-power magni®cation, LL-37 was evident within the
keratinocytes at the wound edge, as well as in granulocytes
(Fig 3A, B), suggesting both cell types may contribute to the
production of cathelicidin after injury. To con®rm that keratino-
cyte cathelicidin staining was the product of endogenous produc-
tion and not due to uptake of material originally synthesized by
granulocytes, cultured skin equivalents comprised only of kerati-
nocytes and ®broblasts were also stained with anti-LL-37. These
cultured skin equivalents showed abundant staining for LL-37 in
the upper granular layer and stratum corneum in a pattern similar to
that seen at the wound edge (Fig 3C).
Figure 2. Cathelicidin is induced during
wound repair. Expression of cathelicidins in
murine and human skin wounds were evaluated
with antibodies to CRAMP or LL-37. CRAMP
expression was detected in murine wounds 6 h
(A) and 5 d (B) after injury using antibody
described in Fig 1. LL-37 was detected with anti-
LL-37 in human wounds 24 h (D) and 5 d (E)
after injury. Cathelicidins are seen in granulation
tissue at the earliest time points examined after
injury. By 5 d CRAMP (B) and LL-37 (E) are
detected strongly in the crust, and faintly in the
re-epithelialized epidermis. No staining was
detected in murine or human sections with
preimmune sera (C, murine; F, human). All
sections were counterstained with hematoxylin as
described in Materials and Methods. Scale bar:
40 mm.
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Cathelicidin mRNA is induced after injury To evaluate
whether cathelicidin induction was occurring at the transcriptional
level, total RNA was prepared from normal skin, skin from the
wound edge 2 or 12 h after injury, and bone marrow. Prior work
with cathelicidin transcripts has shown they are present in many
tissues, including at high levels in bone marrow, but are
undetectable or at low levels in circulating blood or mature
granulocytes (Agerberth et al, 1995; Gallo et al, 1997). CRAMP
mRNA was detected at low levels in RNA from normal skin or
skin 2 h after injury, but was abundantly present in skin 12 h after
injury or in bone marrow that is known to contain abundant
CRAMP mRNA (Fig 4). The presence of increased transcript in
injured skin is similar to the increase in cathelicidin protein
detected in keratinocytes by immunostaining.
Cathelicidin in wounds is processed to the mature
form Cathelicidins are made as a propeptide with an anionic
pro-domain known as the ``cathelin'' region N-terminal to the
mature cationic anti-microbial peptide. Anti-microbial activity of
cathelicidins present in granulocytes can be activated by elastase
cleavage to free the C-terminal active peptide fragment (Zanetti et
al, 1990; Shi and Ganz, 1998). Extraction of murine bone marrow
prior to activation and analysis of CRAMP by SDS/polyacrylamide
gel electrophoresis and western blot demonstrated that the majority
of immunoreactive material is seen as the larger propeptide (Fig 1),
a pattern typical for cathelicidins extracted from normal tissue (Wu
et al, 1999). Additional experiments were performed to determine if
CRAMP present in the wound was processed to the mature 33
amino acid peptide. Five days after wounding, murine wounds and
normal skin controls were extracted and analyzed via western blot
(Fig 5). Extracts from wounds showed abundant CRAMP as the
mature form and little at the expected size of the propeptide (Fig 5,
lane A). Consistent with results from immunohistology, blots of
extracts from normal skin had no detectable CRAMP (Fig 5, lane
B). Extracts of crust from human wounds similarly showed
abundant LL-37 in the mature form (data not shown). Based
upon comparison of the intensity of immunoreactive bands
between crust extracts and a known amount of synthetic peptide,
the approximate amount of CRAMP present in the wound is
0.1 mg per mg total protein.
CRAMP is induced in response to GAS infection GAS is an
important human pathogen responsible for a variety of cutaneous
infections, including impetigo, cellulitis, erysipelas, and wound
infections. A murine model of GAS cutaneous infection was
studied to determine if cathelicidin expression was also induced
Figure 3. Cathelicidin is present in granulocytes and
keratinocytes during wound repair. Human wounds 24 h after injury
were examined at high power (3 630) to determine the location of
cathelicidin expression. (A) LL-37 was detected in the keratinocytes
(arrow) at the site of injury, and (B) abundantly in granulocytes. (C)
Cultured human skin construct (Apligraf) stained for LL-37 as in Fig 2
shows LL-37 expression in the granular layer of keratinocytes and
stratum corneum after differentiation of the epidermis. Staining was not
seen with preimmune sera (D). Scale bar: (A, C, D) 40 mm; (B) 20 mm.
Figure 4. Cathelicidin mRNA is induced in wounds after injury.
Total RNA was extracted from equal amounts of murine skin prior to
injury (A), and 2 or 12 h after injury (B, C). Reverse transcription±PCR
was performed on equal amounts of RNA extracted from each of these
samples and from normal bone marrow as positive control (D). (E)
Water as negative control. The upper band of 607 bp corresponds to the
predicted size of CRAMP cDNA and was present more abundantly 12 h
after injury or in RNA extracted from bone marrow used as a positive
control. The lower band of 202 bp corresponds to the predicted size of
the mouse b-actin PCR product that was simultaneously ampli®ed in
each reaction to demonstrate similar template availability. Molecular
weight (Mw) marker X174 DNA cleaved with HaeIII. CRAMP PCR
products were sequenced to con®rm identity.
Figure 5. Cathelicidin is present in the mature form in wounds.
Western blots were done as described in Fig 1 with antibody against
CRAMP on similar amounts (» 0.2 mg protein) of tissue extracts
prepared from normal murine skin and skin 5 d after injury. Lane A
contains the extract from wounded skin. Lane B contains extract from
normal skin and lane C contains 10 pg pure synthetic CRAMP. A major
band corresponding to the size of the mature peptide was seen in injured
skin extracts. CRAMP was not detectable in the normal skin. Identical
results were seen when 10 times more normal skin extract was loaded
per lane.
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following microbial invasion. Twenty-four hours after inoculation
of GAS mixed with Cytodex beads, mice developed a localized
ulcer with CRAMP abundantly expressed in the crust (Fig 6). This
large deposition of cathelicidin persisted in the skin injured by GAS
for up to 5 d. Cytodex beads alone injected as a control produced a
minor foreign body reaction but no detectable increase in CRAMP
in mice.
Cathelicidins are potent anti-microbial agents against
GAS The induction of cathelicidins in skin following injury or
GAS infection suggests its presence could in¯uence the wound
repair process. Previous work, however, has shown the anti-
bacterial activity of many peptides is active only under optimized
culture conditions, and only against bacteria that are relatively rare
skin pathogens. At physiologic salt concentrations CRAMP, LL-
37, and b-defensins are much less active against most bacteria and
inactive against gram-positive organisms such as Staphylococcus aureus
(Gallo et al, 1997; Bals et al, 1998; Johansson et al, 1998). For the
expression of cathelicidins in skin to be bene®cial as anti-microbials
in the wound repair process, these peptides should inhibit the
growth of relevant wound pathogens in this environment. To
evaluate this, the anti-microbial action of LL-37 and CRAMP was
determined against GAS in culture media (tryptic soy broth, Luria
Broth) designed for optimization of bacterial growth (Chapin et al,
1999) as well as media previously used for anti-microbial peptide
assays (0.5 3 Mueller-Hinton + Medium E). Purity of each
synthetic peptide was con®rmed by high-performance liquid
chromatography analysis. Peptides were also tested against known
susceptible and resistant strains of E. coli and S. aureus and to
con®rm their bioactivity.
The human and murine cathelicidins potently inhibited the
growth of GAS. Low concentrations of CRAMP and LL-37
inhibited growth of most GAS serotypes tested (Table I). Less
activity was observed against groups B and C Streptoccoci. LL-37 and
CRAMP were active against GAS in all culture media tested, not
just those optimized for anti-microbial action. Bacteria such as E.
coli that have been previously shown to be highly susceptible to LL-
37 and CRAMP (MIC 0.15±1.5 mM), were not inhibited by LL-
37 or CRAMP when assayed in these culture conditions. Thus,
GAS is more sensitive to the action of these peptides under these
culture conditions than bacteria previously reported to be highly
sensitive. Additional evidence for the highly potent and stable
action of cathelicidins against GAS was seen by further attempting
to inactivate LL-37 by the addition of NaCl or serum. Inhibition of
E. coli growth by LL-37 is abolished upon addition of serum or in
increased salt conditions. Addition of up to 300 mM NaCl to
culture media only slightly increased MIC values for LL-37 against
GAS from 2 to 4 mM. One percent serum reduced the ability of
1 mM LL-37 to inhibit the of the growth of GAS from > 90% to
50%, but did not abolish activity. Thus, unlike bacterial strains
previously evaluated, cathelicidins inhibit GAS growth under a
range of culture environments.
DISCUSSION
The purpose of this study was to evaluate the expression and
function of cathelicidins following injury to mammalian skin. Small
cationic peptides such as the cathelicidins have been hypothesized
to act as important components of innate immunity, providing an
anti-microbial barrier against infection (Ganz et al, 1985; Zaslof,
1987; Lehrer et al, 1993; Bevins, 1994; Boman, 1996; Gallo and
Huttner, 1998). Initial support for this hypothesis was based on
in vitro observations that members of several anti-microbial gene
families can kill a wide range of bacteria. Further support of the
barrier hypothesis derives from the observation that epithelial
surfaces, such as respiratory and gastrointestinal mucosa, express
these peptides (Goldman et al, 1997; Agerberth et al, 1991, 1999;
Jones and Bevins, 1992; Bals et al, 1998). Despite the potent in vitro
anti-microbial activity and their appropriate tissue distribution,
however, the argument for epithelial innate immunity by
cathelicidins and defensins has been limited by relatively poor
activity of many of these peptides when studied under culture
conditions that more closely resemble those encountered in vivo
(Bals et al, 1998; Johansson et al, 1998). Furthermore, the skin, the
major epithelial organ exposed to the external environment, has
minimal expression of cathelicidins under normal conditions
(Frohm et al, 1997). In our study we show human LL-37, and its
murine homolog CRAMP, are both rapidly expressed in the skin at
the site of injury. Expression occurred in response to a sterile
surgical incision or infection with GAS, and was characterized by
increased mRNA together with increased mature bioactive
cathelicidin. LL-37, or CRAMP, was produced by keratinocytes
and present in granulocytes within the wound. These cathelicidins
were further shown to have potent anti-microbial action against
GAS, an important skin wound pathogen. This anti-microbial
activity was not previously known for the cathelicidins.
Cathelicidins are a diverse group of anti-microbial peptides
characterized by homology in the N-terminal pro-domain and
great diversity in the C-terminal anti-microbial peptide region
(Zanetti et al, 1995). Cathelicidins have been described in pig
(Agerberth et al, 1991), rabbit (Ooi et al, 1990), cow (Selsted et al,
Figure 6. Group A Streptococcal infection induces cathelicidin
expression. Mice were injected subcutaneously with 106 cfu of GAS
strain NZ131 (M49) with Cytodex beads as carrier or with an equal
number of Cytodex beads alone as control. One day after injection skin
sections were immunostained as in Fig 2 for CRAMP. (A) Abundant
CRAMP was detected in the crust of skin injected with Cytodex beads
coated with GAS. (B) CRAMP was not detected in skin following
injection of Cytodex beads alone. Scale bar: 20 mm.






909 (serotype M22) 2 8
NZ131 (serotype M49) 2±16 8±16
317/98 (serotype M59) 1 4
1603/99 (serotype M76) 1 2
Group B Streptococcus
A909 (serotype Ia) >32 >32
M709 (serotype Ib) >32 >32
DK23 (serotype II) >32 >32
K79 (serotype III) 32 >32
Group C Streptococcus (strain SS-188) 16 32
Staphylococcus aureus ATCC no. 25923 >32 >32
Escherichia coli ATCC no. 25922 >32 >32
aMinimal inhibitory concentration (MIC) was de®ned as the lowest concentra-
tion of peptide that inhibited at least 80% of growth after overnight incubation at
37°C in tryptic soy broth. Results were determined on triplicate samples and each
experiment repeated three times.
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1992; Scocchi et al, 1997), sheep (Huttner et al, 1998), horse
(Scocchi et al, 1999), mouse (Gallo et al, 1997), and humans
(Agerberth et al, 1995). The structures of the mature C-terminal
peptides vary between those rich in particular amino acids (PR-
rich: BAC5, BAC7, PR-39; R-rich: P15s; W-rich: indolicidin),
those forming b-sheets with disul®de bonds (protegrins) and those
that are cysteine free and form a-helical structures [LL-37, CAP18
(Larrick et al, 1994) CRAMP]. The function and the spectrum of
anti-microbial activity of cathelicidin family members differs, and
some, like the PR-rich cathelicidins, act also to modify host cell
functions (Gallo et al, 1994; Shi et al, 1996; Korthuis et al, 1999).
Because of this structural and functional diversity, it is important to
compare carefully the cathelicidins when extrapolating from animal
models to humans. The murine cathelicidin CRAMP has proven
to be a particularly useful model because it is similar in many
respects to the human cathelicidin LL-37 (Gallo et al, 1997;
Gudmundsson and Agerberth, 1999). Both represent the sole
cathelicidin in their respective species, map to homologous
chromosomal regions, have highly homologous 5¢-untranslated
regions, and have mature peptide domains that are structurally
conserved with comparable spectra of anti-microbial activity (Gallo
et al, 1997). Owing to their overall similarity, the expression pattern
of both cathelicidins was evaluated in our study. In this fashion,
observations made in human skin could be corroborated and
further explored in a mouse model.
Nearly identical patterns of expression were observed for LL-37
and CRAMP. Immunoreactivity against cathelicidins in skin was
seen only following injury and localized to the wound edge.
Expression persisted for several days and formed a dense super®cial
boundary between the healing wound and the external environ-
ment. LL-37 and CRAMP were clearly seen in at least two cell
types, neutrophils and keratinocytes. The expression of cathelici-
dins in granulocytes likely re¯ects prior synthesis of the stored
propeptide for stimulus-induced release (Zanetti et al, 1990);
however, new synthesis was observed for cathelicidins derived from
keratinocytes. This was most apparent with LL-37, which appeared
in keratinocytes at the wound edge. The production of
cathelicidins in wounded skin resembled the expression seen in
keratinocytes from cultured skin equivalents. Finding LL-37
expression in cultured skin equivalents con®rms that detection of
cathelicidins in whole skin is likely re¯ective of de novo synthesis
and not just due to deposition from in®ltrating granulocytes. These
®ndings were also supported by the appearance of CRAMP
transcripts in wounded mouse skin.
Keratinocytes are the likely source for these transcripts as mature
granulocytes do not contain detectable levels of CRAMP mRNA
(Gallo et al, 1997); however, multiple cell types may contribute to
the production of cathelicidins following injury, both keratinocytes
and granulocytes are signi®cant sources for the anti-microbial
peptide, and tissue-in®ltrating granulocytes may increase CRAMP
mRNA together with keratinocytes. As a whole tissue, injured skin
expressed cathelicidin abundantly whereas uninjured skin did not.
The potential for expression by keratinocytes enables rapid site-
speci®c delivery independent of the time necessary for leukocyte
recruitment. Interestingly, the ability of cultured skin equivalents to
produce cathelicidins constitutively suggests that unlike normal
skin, this tissue could act similar to wounded skin. The signi®cance
of cathelicidin expression in the wound and in skin equivalents lies
in understanding its function.
To investigate the function of cathelicidins as a barrier to wound
infection, the range of bacteria tested for susceptibility was
increased to include additional wound pathogens. Prior studies of
CRAMP and LL-37 have shown poor anti-microbial action (MIC
> 64 mM) against the common skin pathogen S. aureus, better
activity (MIC 4±16 mM) against the burn pathogen Pseudomonas
aeruginosa, and best activity (MIC 5±16 mM) against E. coli and
other species that rarely infect skin (Gallo et al, 1997; Bals et al,
1998; Johansson et al, 1998; Turner et al, 1998). In the most
susceptible bacteria, LL-37 action was dependent on the optimiza-
tion of assay conditions. Anti-microbial activity was inactivated
when bound to serum elements or when assayed in standard
bacterial culture media (Johansson et al, 1998; Wang et al, 1998).
When assayed under the bacterial growth conditions used in this
study, LL-37 and CRAMP both had poor activity against E. coli
(Table I). These ®ndings argue against action as a broad-spectrum
anti-microbial agent despite observations of their anti-microbial
activity in other assay systems (Travis et al, 2000), and ®nding that
cathelicidins are present in wound ¯uids at concentrations suf®cient
to inhibit bacterial growth if assayed under optimal anti-microbial
conditions (Frohm et al, 1996; Shi and Ganz, 1998).
Our results show that the cathelicidins are potent selective
inhibitors of GAS, one of the most prevalent and potentially
invasive skin pathogens. This activity was con®rmed for four
different GAS isolates belonging to characteristic serotypes associ-
ated with skin infection. The amount of cathelicidin present in the
wound was estimated in the present study to be » 0.1 mg per mg
total protein. A conservative estimate of the total protein per
volume available at the wound of 100 mg per ml yields a
concentration of CRAMP as 3±10 mM, within the MIC. In
contrast, LL-37 and CRAMP were not effective inhibitors of the
closely related group B and C Streptoccoci, which more frequently
occupy niches on the respiratory, gastrointestinal, or vaginal
mucosa. The spectrum of GAS infections in skin range from self-
limited impetigo to the potentially life-threatening necrotizing
fasciitis. Relevant to its activity against this infectious skin organism,
CRAMP is present in the skin after GAS infection and deposited
within the scale crust of the necrotic lesion. This expression of
cathelicidin could, therefore, re¯ect a speci®c defense mechanism
by the skin to limit the proliferation of GAS. Alternatively,
expression may be a nonspeci®c response to the tissue injury
mediated by GAS. Given the induction of expression by sterile
surgical incision, the latter explanation is more likely. Further work
is required to explore the mechanisms responsible for regulation of
cathelicidin expression.
Cathelicidins have been described to have several other functions
in addition to anti-microbial activity such as induction of
proteoglycan expression (Gallo et al, 1994) effects on neutrophil
migration and chemotactic activity (Huang et al, 1997), and
induction of apoptosis (Risso et al, 1998). These ®ndings suggest
the possibility that expression can function in wound repair
through mechanisms that act directly on the cells of the wound
environment and not solely against microbial pathogens. This
hypothesis remains to be directly tested, but does not exclude the
bene®t to the wound repair process that deposition of a potent
inhibitor of GAS growth offers.
In summary, this study demonstrates that cathelicidin expression
is a characteristic of the response of the skin to injury. Functionally,
the signi®cance of this response lies (at least in part) in the newly
recognized ability of human and murine cathelicidins to inhibit
growth of GAS under conditions that would not permit anti-
microbial function against other bacteria. Cathelicidins, possibly
combined with other anti-microbial peptides, such as the newly
described b-defensin-3 in the skin, suggest that evolutionarily
ancient systems of innate defense by anti-microbial peptides can
function in specialized situations during human wound repair.
Understanding these events and their application may help in the
diagnosis and therapy of several human diseases.
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